B. Riley Forecasts Lineage Cell Therapeutics Q1 Earnings

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) - Analysts at B. Riley issued their Q1 2025 earnings estimates for shares of Lineage Cell Therapeutics in a report issued on Thursday, March 13th. B. Riley analyst M. Mamtani expects that the company will post earnings per share of ($0.03) for the quarter. B. Riley has a "Buy" rating and a $3.00 price objective on the stock. The consensus estimate for Lineage Cell Therapeutics' current full-year earnings is ($0.12) per share. B. Riley also issued estimates for Lineage Cell Therapeutics' Q2 2025 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.03) EPS and FY2027 earnings at ($0.08) EPS.

A number of other brokerages also recently weighed in on LCTX. Maxim Group dropped their target price on shares of Lineage Cell Therapeutics from $5.00 to $3.00 and set a "buy" rating for the company in a research note on Friday, January 10th. D. Boral Capital reissued a "buy" rating and set a $2.00 price target on shares of Lineage Cell Therapeutics in a research note on Tuesday, March 11th. Finally, HC Wainwright reissued a "buy" rating and set a $9.00 price target on shares of Lineage Cell Therapeutics in a research note on Tuesday, March 11th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $4.20.

Lineage Cell Therapeutics Trading Up 3.4 %

Shares of NYSEAMERICAN LCTX traded up $0.02 during trading on Monday, reaching $0.51. The company had a trading volume of 1,760,663 shares, compared to its average volume of 1,247,114. Lineage Cell Therapeutics has a 52 week low of $0.48 and a 52 week high of $1.61. The stock has a market cap of $112.63 million, a PE ratio of -4.26 and a beta of 1.21. The business's 50 day moving average is $0.60.

Remove Ads

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Squarepoint Ops LLC acquired a new position in shares of Lineage Cell Therapeutics in the fourth quarter valued at approximately $46,000. Two Sigma Advisers LP boosted its holdings in shares of Lineage Cell Therapeutics by 312.2% in the fourth quarter. Two Sigma Advisers LP now owns 86,964 shares of the company's stock valued at $44,000 after buying an additional 65,864 shares during the period. Two Sigma Investments LP acquired a new position in shares of Lineage Cell Therapeutics in the fourth quarter valued at approximately $152,000. Jacobs Levy Equity Management Inc. acquired a new position in shares of Lineage Cell Therapeutics in the fourth quarter valued at approximately $519,000. Finally, Deutsche Bank AG boosted its holdings in Lineage Cell Therapeutics by 196.0% during the fourth quarter. Deutsche Bank AG now owns 174,702 shares of the company's stock worth $87,000 after purchasing an additional 115,672 shares during the last quarter. Institutional investors and hedge funds own 62.47% of the company's stock.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.